Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00893113 · ClinicalTrials.gov registry record · Phase 3

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

A Phase 3 study of Erectile Dysfunction and Lower Urinary Tract Symptoms, sponsored by Chesapeake Urology Research Associates.

Completed
Registry status
Phase 3
Development phase
74
Enrollment target
4
Study locations

NCT00893113: Completed Phase 3 study of Erectile Dysfunction and Lower Urinary Tract Symptoms, sponsored by Chesapeake Urology Research Associates.

NCT00893113 is a Phase 3 study of Erectile Dysfunction and Lower Urinary Tract Symptoms that has completed, run by Chesapeake Urology Research Associates. The registered enrollment target is 74 participants, below the 229-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00893113, a Phase 3 study of Erectile Dysfunction and Lower Urinary Tract Symptoms, has completed, sponsored by Chesapeake Urology Research Associates.

COMPLETED
Registry status
Phase 3
Development phase
74 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International Index of Erectile Function (IIEF).

Primary Outcome

The International Index of Erectile Function (IIEF) is used for the evaluation of male sexual function and diagnostic evaluation of Erectile Dysfunction (ED) severity. There are 5 domains of the IIEF: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The Erectile Function (EF) domain of the IIEF is used to assess specific key components of ED including ability to achieve penetration and ability to maintain erection sufficient for satisfactor

Interventions

  • DRUG Placebo
  • DRUG Alfuzosin

Study Locations (4)

Maryland

  • Chesapeake Urology Research Associates - Baltimore
  • Chesapeake Urology Research Associates - Baltimore
  • Chesapeake Urology Research Associates - Glen Burnie
  • Chesapeake Urology Research Associates - Towson

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2009-06
Est. Completion 2012-10
Phase Phase 3

What the finished NCT00893113 record still lists

NCT00893113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 229-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00893113 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00893113 about?

NCT00893113 is a clinical study titled "An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms". The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International Index of Erectile Function (IIEF).

What is the current status of trial NCT00893113?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2009-06. Estimated completion is 2012-10.

What conditions does trial NCT00893113 study?

This clinical trial studies the following conditions: Erectile Dysfunction, Lower Urinary Tract Symptoms.

What interventions are being tested in trial NCT00893113?

The interventions under investigation include: Placebo (DRUG), Alfuzosin (DRUG).

Who is sponsoring clinical trial NCT00893113?

This trial is sponsored by Chesapeake Urology Research Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00893113 being conducted?

This trial has 4 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Erectile Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00893113's enrollment target sits among peer trials

74 17th of 33 higher than 17 of 33 other Erectile Dysfunction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00893113, the US trial registry maintained by the National Library of Medicine. NCT00893113 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.